OBJECTIVES: We sought to develop and apply a new scheme for the classification of death to be used in trials of antiarrhythmia treatments. BACKGROUND: Because presently accepted classifications of death do not fully describe or tabulate all significant aspects of terminal events, nor do they consider unique aspects of arrhythmia investigations, a new classification scheme that addresses these issues is desirable. METHODS: A classification scheme of deaths that occur in antiarrhythmia trials was developed using the following categories: 1) primary organ cause (cardiac [arrhythmic, nonarrhythmic or unknown], noncardiac or unknown); 2) temporal course (sudden, nonsudden or unknown); 3) documentation (witnessed, monitored [yes, no or unknown]); 4) operative relation (preoperative, perioperative or postoperative); and 5) system relation (procedure related, pulse generator related and lead related [yes, no or unknown]). RESULTS: The classification scheme was used in a clinical trial of a new implantable cardioverter-defibrillator (1,250 patients, of whom 79 died) and used in an application for device market approval. Application of the classification to data reported using an older classification scheme is demonstrated. CONCLUSIONS: We propose a descriptive classification scheme that 1) fully describes and tabulates all significant aspects of terminal events; 2) incorporates previously used categorizations of death and new categorizations that address unique aspects of arrhythmia investigations; and 3) tabulates sufficient data to allow comparison with other studies. Events in a clinical trial of implantable defibrillator therapy were classified using the new classification scheme.
OBJECTIVES: We sought to develop and apply a new scheme for the classification of death to be used in trials of antiarrhythmia treatments. BACKGROUND: Because presently accepted classifications of death do not fully describe or tabulate all significant aspects of terminal events, nor do they consider unique aspects of arrhythmia investigations, a new classification scheme that addresses these issues is desirable. METHODS: A classification scheme of deaths that occur in antiarrhythmia trials was developed using the following categories: 1) primary organ cause (cardiac [arrhythmic, nonarrhythmic or unknown], noncardiac or unknown); 2) temporal course (sudden, nonsudden or unknown); 3) documentation (witnessed, monitored [yes, no or unknown]); 4) operative relation (preoperative, perioperative or postoperative); and 5) system relation (procedure related, pulse generator related and lead related [yes, no or unknown]). RESULTS: The classification scheme was used in a clinical trial of a new implantable cardioverter-defibrillator (1,250 patients, of whom 79 died) and used in an application for device market approval. Application of the classification to data reported using an older classification scheme is demonstrated. CONCLUSIONS: We propose a descriptive classification scheme that 1) fully describes and tabulates all significant aspects of terminal events; 2) incorporates previously used categorizations of death and new categorizations that address unique aspects of arrhythmia investigations; and 3) tabulates sufficient data to allow comparison with other studies. Events in a clinical trial of implantable defibrillator therapy were classified using the new classification scheme.
Authors: Claudio Schuger; James P Daubert; Mary W Brown; David Cannom; N A Mark Estes; W Jackson Hall; Torsten Kayser; Helmut Klein; Brian Olshansky; Keith A Power; David Wilber; Wojciech Zareba; Arthur J Moss Journal: Ann Noninvasive Electrocardiol Date: 2012-07 Impact factor: 1.468
Authors: David D Daly; Anbukarasi Maran; J Madison Hyer; Frederick Funke; Ashley Waring; Frank A Cuoco; J Lacy Sturdivant; Robert B Leman; Michael R Gold Journal: Pacing Clin Electrophysiol Date: 2016-06-07 Impact factor: 1.976
Authors: Manesh R Patel; Peter J Cawley; John F Heitner; Igor Klem; Michele A Parker; Wael A Jaroudi; Trip J Meine; James B White; Michael D Elliott; Han W Kim; Robert M Judd; Raymond J Kim Journal: Circulation Date: 2009-11-02 Impact factor: 29.690
Authors: Alan H Kadish; David Bello; J Paul Finn; Robert O Bonow; Andi Schaechter; Haris Subacius; Christine Albert; James P Daubert; Carissa G Fonseca; Jeffrey J Goldberger Journal: J Cardiovasc Electrophysiol Date: 2009-07-01
Authors: G N Kay; K A Ellenbogen; M Giudici; M M Redfield; L S Jenkins; M Mianulli; B Wilkoff Journal: J Interv Card Electrophysiol Date: 1998-06 Impact factor: 1.900
Authors: John D Fisher; Alfred E Buxton; Kerry L Lee; Douglas L Packer; Debra S Echt; Pablo Denes; Michael H Lehmann; John P DiMarco; Denis Roy; Gail E Hafley Journal: Am J Cardiol Date: 2007-05-11 Impact factor: 2.778